Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

96
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
96
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

190
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
190
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

458
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
458

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ASO Author Reflections: Trials and Tribulations of Managing Recurrent Uterine Leiomyosarcoma.

Annals of surgical oncology·2026
Same author

ASO Visual Abstract: Efficacy and Safety of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Uterine Leiomyosarcoma: Results of a Phase 2 Study.

Annals of surgical oncology·2026
Same author

A Pan-Cancer Single-Cell Atlas to Evaluate Tumor Identity, Cell Line Concordance, and Dependency Mapping.

bioRxiv : the preprint server for biology·2026
Same author

Efficacy and Safety of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Uterine Leiomyosarcoma: Results of a Phase 2 Study.

Annals of surgical oncology·2026
Same author

Long-term quality of life, financial toxicity, and decision regret following therapeutic and prophylactic gastrectomy for cancer.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2026
Same author

Overcoming CXCR4-Mediated T-Cell Exclusion Potentiates Antitumor Cytotoxicity in Fibrolamellar Carcinoma.

Gastroenterology·2026

Related Experiment Video

Updated: Jul 11, 2025

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

1.9K

PIPAC for Gastrointestinal Malignancies.

Sara K Daniel1, Beatrice J Sun1, Byrne Lee1

  • 1Department of Surgery, Stanford University, Stanford, CA 94305, USA.

Journal of Clinical Medicine
|November 14, 2023
PubMed
Summary
This summary is machine-generated.

Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) offers a minimally invasive option for peritoneal metastases (PMs), potentially improving outcomes for patients ineligible for cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC). This approach enhances drug delivery and may increase survival with reduced morbidity.

Keywords:
PIPACintraperitoneal chemotherapyperitoneal metastases

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.1K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

740

Related Experiment Videos

Last Updated: Jul 11, 2025

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

1.9K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.1K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

740

Area of Science:

  • Oncology
  • Surgical Oncology
  • Gastroenterology

Background:

  • Peritoneal metastases (PMs) from gastrointestinal tumors are associated with poor prognosis and reduced quality of life.
  • Current treatments like cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) are effective but have limitations, particularly for high disease burden.
  • The unique properties of the blood-peritoneum barrier make the peritoneum a target for regional therapies.

Purpose of the Study:

  • To review the rationale and benefits of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC).
  • To discuss the application of PIPAC for various gastrointestinal malignancies with peritoneal metastases.
  • To explore the potential role of PIPAC in neoadjuvant/adjuvant and palliative settings.

Main Methods:

  • Review of sentinel papers and existing literature on PIPAC for peritoneal metastases.
  • Discussion of the mechanism of action and drug distribution advantages of PIPAC.
  • Analysis of clinical trial data and future directions for PIPAC implementation.

Main Results:

  • PIPAC improves drug distribution and tissue penetration compared to conventional chemotherapy.
  • It offers a minimally invasive approach for patients unsuitable for CRS/HIPEC due to high disease burden.
  • Early studies suggest PIPAC may convert unresectable disease to resectable and improve survival with acceptable morbidity.

Conclusions:

  • PIPAC is an emerging regional therapy for peritoneal metastases with potential to improve outcomes.
  • Further research and FDA approval are needed to integrate PIPAC into standard treatment paradigms.
  • PIPAC shows promise in managing gastric, colorectal, appendiceal, and pancreatobiliary peritoneal metastases.